Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Raltegravir - Merck & Co

Next Previous
Drug Profile

Raltegravir - Merck & Co

Alternative Names: Isentress; ISENTRESS HD; L 900612; MK-0518; RAL

Latest Information Update: 29 Feb 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Merck & Co
  • Developer Merck & Co; Merck Sharp & Dohme; National Institute of Allergy and Infectious Diseases; The French National Agency for Research on AIDS and Viral Hepatitis; University of Alberta
  • Class Antiretrovirals; Naphthyridines; Organic chemicals; Small molecules
  • Mechanism of Action HIV integrase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - HIV-1 infections
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed HIV-1 infections
  • Phase II Primary biliary cirrhosis

Most Recent Events

  • 01 Jan 2024 University of Alberta in collaboration with Merck Sharp & Dohme completes a phase II trial in Primary biliary cirrhosis (Combination therapy) in Canada (PO) (NCT03954327)
  • 02 Jan 2023 Raltegravir is still in phase II trials for Primary biliary cirrhosis in Canada (PO) (NCT03954327)
  • 02 Jan 2023 No development reported - Phase-III for HIV-1 infections (Combination therapy, Treatment-naive) in Vietnam and Mozambique (PO)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top